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Disturbances of the cerebral cholinergic neurotransmitter system are present in neurodegenerative disorders. SPECT or PET
imaging, using radiotracers that selectively target muscarinic receptor subtypes, may be of value for in vivo evaluation of such
conditions.6β-acetoxynortropane, a potent muscarinicM2 receptor agonist,has previously demonstrated nanomolaraﬃnity and
high selectivity for this receptor. Based on this compound we synthesized four nortropane derivatives that are potentially suitable
for SPECT imaging of the M2 receptor. 6β-acetoxynortropane and the novel derivatives were tested in vitro for aﬃnity to the
muscarinic M1−3 receptors. The original 6β-acetoxynortropane displayed high aﬃnity (Ki = 70–90nM) to M2 receptors and
showed good selectivity ratios to the M1 (65-fold ratio) and the M3 (70-fold ratio) receptors. All new derivatives showed reduced
aﬃnity to the M2 subtype and loss of subtype selectivity. It is therefore concluded that the newly synthesized derivatives are not
suitable for human SPECT imaging of M2 receptors.
1.Introduction
Central cholinergic disturbances are present in many neu-
ropsychiatric and neurodegenerative diseases. In various
forms of dementia, such as Alzheimer’s dementia (AD) or
Lewy body dementia, cholinergic deﬁcits in the brain [1, 2]
are associated with cognitive decline [3–5] and are thought
to precede clinical symptoms.
The majority of the cholinergic deﬁcits in these diseases
arisefromdegenerativeeventsinbasalforebrainregionssuch
as the nucleus basalis of Meynert [6, 7], which provides
the cholinergic input of the cerebral cortex. In degenerative
diseases such as AD,disruption ofbasal cholinergic forebrain
projections leads to a presynaptic cholinergic defect in corti-
calbrainareas [1,8].Beingpart ofafamily ofﬁvemuscarinic
receptor subtypes, the muscarinic M2 receptor is located
predominantly presynaptically [9] and is consequently a
potential target for the evaluation of the integrity of the
cholinergic neurotransmitter system by molecular imaging.
In vivo assessment of the central cholinergic system in
patients suﬀering from dementia by means of positron emis-
siontomography(PET) orsingle photonemission computed
tomography (SPECT) may be of value for early diagnosis or
monitoring of such diseases, to predict response to choliner-
gic therapies (such as acetylcholinesterase inhibitors) or to
evaluate eﬀects of experimental drugs. Molecular imaging
of the cholinergic system of the brain requires radiotracers
that ideally selectively target speciﬁc neuroreceptors of
this neurotransmitter system, such as the muscarinic M2
receptor.
Many attempts have been made to develop muscarinic
receptor subtype selective radiotracers [10–12]. Currently,
amongst the most promising of these potential tracers is
[18F]FP-TZTP [10, 13, 14], which has selectivity for the2 International Journal of Molecular Imaging
muscarinic M2 receptor [15] and has been applied success-
f u l l yi ns e v e r a lh u m a nP E Ts t u d i e s[ 16–18].
Iodine-123 has favorable properties for SPECT imaging
of neuroreceptors[19–23]. The abundant 159keVγ photons
of 123I (83% abundancy) are suitable for high-resolution
brain SPECT imaging using LEHR (Low Energy High Res-
olution) or fanbeam collimators. Furthermore, unlike 18F-
labeled radiopharmaceuticals (T1/2 = 109.8min), thehalf-
life of 13.2 hours permits transportation over long distances
of centrally produced 123I-labeled radiopharmaceuticals, for
instance, to the majority of European nuclear medicine
centers from a single manufacturing site. Moreover, suitable
methods have been developed for convenient radiosynthesis
of radiopharmaceuticals labeled with 123I selectively at one
appropriate position with high radiochemical yields, for
instance, by oxidative iododestannylation [24]. However,
radioiodinated SPECT analogues of TZTP so far have demo-
nstrated disappointing results in vivo [25]. Radioiodinated
Z-IQNP is another compound that has recently been
evaluated for imaging of the muscarinic M2 receptor [12,
26], although the muscarinic subtype selectivity of this
compound for the M2 receptor subtype is limited.
Recently, 6β-acetoxynortropane, a tropane alkaloid, was
reported to be a potent and highly selective agonist for
muscarinic M2 receptors [27], and radiolabeled derivatives
of this compound may thus be of value for in vivo imaging
of these receptors. Moreover, as compared with the men-
tioned TZTP analog these nortropane analogs havefavorable
physicochemical properties. Notably, the lipophilicity of
iodinated nortropane compounds remains in the optimal
range 1–3of logD (pH 7.4).The logD (pH 7.4) of iodinated
TZTP compounds, on the other hand, is too high (i.e., >4),
likely resulting in a high degree of nonspeciﬁc binding in the
brain. In order to obtain good in vivo stability, the iodine
label should be bound to an sp2-carbon, where iodoallyl-
andiodophenylcompoundsarethemostsuitablecandidates.
Of these, iodophenyl compounds are synthetically the most
accessible and more stable.
Based on 6β-acetoxynortropane, we synthesized four
derivatives as potential radiotracers for use in SPECT imag-
ing. The four synthesized nortropane derivatives were tested
for aﬃnity to cloned human muscarinic M1–M3 receptor
subtypes on membrane fractions of Chinese hamster ovary
(CHO) cells by in vitro competitive binding assays.
2.MaterialandMethods
Two nortropane analogues with an iodine containing moiety
onthe 6β-position havebeensynthesized. The tropane skele-
ton was formed in a single-step multicomponent reaction
in analogy to the classical Robinson tropinone synthesis
[28,29],asdisplayedinFigure 1.The resulting tropinonewas
reduced under Wolﬀ-Kishner conditions to give 6-hydroxy-
N-benzylnortropane (3). Alkylation or acylation of the
hydroxyl function of 3resulted in 4a–c,which were debenzy-
latedintwosteps[29,30] toprovide the previously described
6β-acetoxynortropane (5a) ,a n di t si o d i n a t e da n a l o g u e s ,t h e
6β-4 -iodobenzyl ether (5b)o rt h e6 β-4 -iodobenzoate ester
(5c)o f6 β-nortropinol, respectively.
Accordingly, a bromophenyl ring was introduced at the
3β-position. First, the 6-hydroxyfunction of tropinone (2)
was protected as tert-butyldimethylsilyl ether. With a Grig-
nardreaction4-bromophenylwasintroducedattheC3ofthe
tropane. According to the signal of the C6α-H in the proton
NMR spectrum, only the isomer with the 4-bromophenyl
in the equatorial position had been formed. Desilylation
followed by acetylation yielded 3β-(4-bromophenyl)-6β-
acetoxy-N-benzyl nortropane (9).
The benzyl group was removed by hydrogenation, but
simultaneously also the bromo substituent was removed
to result in 3α-hydroxy-3β-phenyl-6β-acetoxy-nortropane
(10b). In one occasion also the 3β-phenyl-6β-acetoxy-nor-
tropane (10a) was isolated, presumably due to the presence
of a small amount of acid.
Relative binding aﬃnity and selectivity ratios of the var-
ious nortropane derivatives for the M1–M3 were determined
by competitive binding assays against [3H]N-methylscopol-
amine ([3H]NMS, Perkin Elmer, Waltham, USA; speciﬁc
activity 78Ci (2886GBq)/mmol). Assays were performed on
membrane suspensions from CHOcells expressing eitherthe
recombinant human muscarinic M1,M 2, or the M3 receptor
subtype (Perkin Elmer, Waltham, USA) [25].
Inthe competitive binding assays, incubationbuﬀercon-
tained 50mM TRIS-HCl, 10mM MgCl2,a n d1m ME D T A
(pH 7.4 at 4◦C). The assays were incubated during 60min
(M1 or M2 receptor subtypes) or 120min (M3 receptor
subtypes) at 27◦C. Nonspeciﬁc binding was determined
using atropine as a competitor in a concentration of 1μM.
In the ﬁrst series of competitive binding assays, the 6β-
4 -iodobenzyl ether (5b)a n dt h e6 β-4 -iodobenzoate ester
(5c)o f6 β-nortropinol, as well as the lead compound 6β-
acetoxynortropane (5a), were tested. Protein concentrations
for undiluted receptor subtype suspensions were 1.2mg/mL
(M1), 4.3mg/mL (M2), and 2.0mg/mL (M3). Aliquots
(n = 3) of diluted membranes (factor 1:100) containing
the M1–M3 receptor subtypes were incubated in a total
volume of 540μL containing 500μL diluted membranes,
20μL[ 3H]NMS, and 20μL of the nortropanes in increasing
concentrations. The [3H]NMS was used in a ﬁnal concen-
tration of 0.2nM for the M1 and M2 assays and 0.09nM
for the M3 assays. The equilibrium dissociation constants in
nM of [3H]NMS for the three receptor subtypes, provided
by the manufacturer, were 0.15 (M1), 0.19 (M2), and 0.08
(M3). Final competitor concentrations ranged from 1.0 ·
10
−10 Mt o1 .0 · 10
−4 M. After incubation, the reaction was
rapidly terminated by vacuum ﬁltration over GF/C glass
ﬁber ﬁlters, presoaked in 0.3% polyethylenimine (Sigma-
Aldrich, Munich, Germany), and washed 5 times with 1mL
of ice-cold buﬀer. Filters were placed in vials with 10mL
of scintillation ﬂuid (Ultima Gold, Perkin Elmer, Waltham,
USA) and counted in a liquid scintillation counter (Tri-Carb
2900 TR Liquid Scintillation Analyzer, Packard. Software
version: 3100).
In the second series of competitive binding assays, de-
rivative 10a and 10b and the lead compound 6β-acetox-
ynortropane (5a) were tested. In this series, the proteinInternational Journal of Molecular Imaging 3
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Figure 1: Reagents and conditions: (i) NH2NH2, NaOH; (ii) Ac2O, pyridine; (iii) 4-Iodobenzyl bromide, DMF; (iv) 4-Iodobenzoyl
chloride, DMAP, Et3N, CH2Cl2;( v )α-chloroethyl chloroformate, Toluene; (vi) MeOH; (vii) TBDMSCl, DMAP, Et3N, DMF; (viii) Mg, 1,4-
dibromobenzene, THF; (ix) HCl (2M), THF, EtOH (1/1/1); (x) Ac2O, pyridine; (xi) H2,P d / C .V a r i a n t s4a–c:R( a)C H 3CO, (b) p-IPhCH2,
and (c) p-IPhCO.4 International Journal of Molecular Imaging
concentrations for undiluted receptor subtype suspensions
were 0.6mg/mL (M1), 7.5mg/mL (M2), and 1.5mg/mL
(M3). Aliquots (n = 4) of diluted membranes (factor
1:30) containing the M1,M 2,o rM 3 receptor subtype were
incubated on a microplate in volumes of 190μL containing
150μL diluted membranes, 20μL[ 3H]NMS, and 20μLo f
thenortropanes in increasing concentrations.In theseassays,
the [3H]NMS was used in a ﬁnal concentration of 0.13nM
for the M1 and M2 assays and 0.065nM for the M3 assays.
The Kd in nM of [3H]NMS in these experiments were as
stated above. Final competitor concentrations ranged from
1.0·10
−10 Mt o1.0·10
−5 M.After incubation,theassays were
ﬁltrated over UniFilter 96 GF/C ﬁlter plates, presoaked in
0.3% polyethylenimine (Sigma-Aldrich, Munich, Germany),
and washed 9 times with 200μL of ice-cold buﬀer. 30μL
of scintillation ﬂuid (MicroScint, Perkin Elmer, Waltham,
USA) was added, and the ﬁlter plates were counted in a
liquid scintillation counter (TopCount 5.0 Liquid Scintil-
lation Analyzer, Perkin Elmer, Waltham, USA). For each
competitor, the inhibition constant (Ki) was calculated from
the EC50 for the muscarinic M1,M 2,a n dM 3 subtypes with
nonlinear regression curve ﬁtting using Graphpad Prism
(version 3.02), relative to the Kd of [3H]NMS as provided by
the manufacturer.
3.Results
In Figure 2, the results of the competitive binding experi-
ments are displayed. The aﬃnity of 6β-acetoxynortropane,
relative to [3H]NMS,forthemuscarinic M2 receptor subtype
proved to be high in both experiments. In the ﬁrst exper-
iment the Ki of 6β-acetoxynortropane was determined as
88.1 ± 23.8nM (average ± SD; n = 3) and in the second
experiment as 71.6 ± 4.8nM(average± SD; n = 4). In our
experiments, selectivity ratios of the compound for the M2
over M1 or M3 receptor subtype proved to be approximately
65 and 70, respectively.
The 6β-4 -iodobenzyl ether of 6β-nortropinol (5b)p e r -
formed substantially less than 6β-acetoxynortropane and
displayed a Ki of only 3.0 ± 0.7μM, while selectivity for the
M2 receptor was lost. The selectivity ratios of this derivative
for the M2 over the M1 and M3 receptors of the compound
were determined as 0.1 and 0.2, respectively.
The 6β-4 -iodobenzoate ester of 6β-nortropinol (5c)
also performed less than 6β-acetoxynortropane, and a Ki of
6.8 ±1.5μM was estimated for the M2 receptor, while selec-
tivity ratios over the M1 and M3 receptor, were determined
as 0.6 and 2.0, respectively.
The second series of experiments (Figure 2), using
3β-phenyl-6β-acetoxynortropane (10a) and 3α-hydroxy-3β-
phenyl-6β-acetoxynortropane (10b) as competitors, likewise
showed weak aﬃnity for muscarinic receptors, and small
competitive eﬀects to the binding of [3H]NMS were only
detectedat the highest concentrationof thetested range. The
aﬃnity for the muscarinic receptors could therefore not be
assessed for these two derivatives.
4.Discussion
In the present study, we have synthesized derivatives that
are based on 6β-acetoxynortropane, a tropane alkaloid
described by Pei and coworkers, which was shown to be
a muscarinic agonist with high aﬃnity to muscarinic M2
receptor subtypes, but lower aﬃnity to other muscarinic
receptor subtypes [27]. Due to the apparent selectivity of
6β-acetoxynortropane for the M2 receptor, the compound
may be of interest for use as a muscarinic receptor radio-
tracer.
Two analogues of the tracer were synthesized in which
the acetyl ester moiety on the 6β-position was replaced
by either 4 -iodobenzyl ether (5b)o ra4  -iodobenzoate
ester (5c). The competitive binding assays demonstrated
that the substitution on the 6β-position of the tropane
skeleton had shifted the aﬃnity from the nanomolar range
to the micromolar range and that the selectivity of the
alkaloid for the M2 receptor subtype was lost. Therefore,
two other analogues were synthesized retaining the 6β-
acetoxy function, with substitution of a phenyl moiety
on the 3β-position of the tropane skeleton: 3β-phenyl-
6β-acetoxynortropane (10a)a n d3 α-hydroxy-3β-phenyl-6β-
acetoxynortropane (10b). Unfortunately, these derivatives
demonstrated even less favorable aﬃnity for the three tested
muscarinic receptor subtypes.
T h ec h a l l e n g eo ft h ep r e s e n ts t u d yw a st oc r e a t ea
derivative of 6β-acetoxynortropane that is suitable for
(radio)iodination, while preserving the aﬃnity for the M2
receptor, optimizing lipophilicity to allow optimal blood-
brain-barrier (BBB) penetration and to limit nonspeciﬁc
uptake, maintaining the size of the molecule as small as
possible, while not compromising metabolic stability.
In an earlier study, our group evaluated the potential M2
receptor tracer E-iodopentenyl-thio-TZTP, which showed
moderate selectivity for the muscarinic M2 receptor over the
M1 and M3 receptors in vitro [25], although selectivity for
M2 receptors was less than the original FP-TZTP [10, 14].
However, in vivo experiments using the TZTP derivative
proved to be unsuccessful due to high lipophilicity of the
tracer and very rapid metabolism of the parent compound
[10, 14]. The 6β-acetoxynortropane derivatives that were
synthesized and evaluated in the present study have several
advantages over the earlier tested TZTP derivative(s). The
lipophilicityofderivative5band5coriodinatedanaloguesof
10aand10bislessthanthatoftheearliersynthesized TZTPs,
being within the estimated logP (P = partition coeﬃcient in
octanol-buﬀer at pH 7.4) range between 1 and 2 (data not
shown), which is considered to be optimal for penetration of
the BBB. Incorporation of an ester function such as in the
6β-4 -iodobenzoate ester of 6β-nortropinol (5c), 3β-phenyl-
6β-acetoxynortropane (10a)oran additional hydroxyl group
in 3α-hydroxy-3β-phenyl-6β-acetoxynortropane (10b)c o n -
tributes to the reduction in lipophilicity as compared to
the earlier reported TZTPs, which should theoretically limit
nonspeciﬁc uptake of these potential tracers in the brain.
Another advantage over the earlier tested TZTP derivatives
is the position of the iodine atom. Although the previous
TZTP derivatives also contained a sp2 carbon-bound iodine,International Journal of Molecular Imaging 5
−4 −5 −6 −7 −8 −9 −10






















−5 −6 −7 −8 −9 −10






















−4 −5 −6 −7 −8 −9 −10






















−5 −6 −7 −8 −9 −10






















−4 −5 −6 −7 −8 −9 −10
Log molar [competitor]






















6β-4 -iodobenzyl ether of 6β-nortropinol
6β-4 -iodobenzoate ester of 6β-nortropinol
Atropine
(e)
−5 −6 −7 −8 −9 −10
Log molar [competitor]


























Figure 2: Competition curves of 6β-acetoxynortropane (5a, Ki for M2 in two separate experiments 88.1nM and 71.6nM, resp.) and the
6β-4 -iodobenzyl ether (5b, Ki for M2 3.0μM) and 6β-4 -iodobenzoate ester (5c, Ki for M2 6.8μM) of 6β-nortropinol, 3β-phenyl-6β-
acetoxynortropane (10a, Ki for M2 > 1μM), and 3α-hydroxy-3β-phenyl-6β-acetoxynortropane(10b, Ki for M2 > 1μM) to the binding of
[3H]NMS to the muscarinic receptor subtypes M1–M3.I nt h ec u r v e so f( a ,c ,e )( d e r i v a t i v e s5a, 5b, 5c), data are expressed as means ± SEM
from 3 samples in a range of 1.0 · 10
−10 Mt o1 .0 · 10
−4 M of competitor concentrations. In the curves of (b, d, f) (derivatives 5a, 10a, 10b),
data are expressed as means ± SEM from 4 samples in a rangeof 1.0·10
−10 Mt o1 .0·10
−5 M ofcompetitor concentrations.Atropine curves
are also displayed as a reference.
this was substituted on the alkenyl side chain, whereas in the
present 6β-4 -iodobenzyl ether (5b)a n d6 β-iodobenzoate
ester of 6β-nortropinol (5c) ,t h ei o d i n ei sb o u n dt oa n
aromatic sp2 carbon atom, which favors the in vivo stability
and prevents rapid deiodination. Although we did not test
iodinatedversionsof3β-phenyl-6β-acetoxynortropane (10a)
and3α-hydroxy-3β-phenyl-6β-acetoxynortropane (10b),the
phenyl ring would also be the appropriate location for
coupling of the iodine atom in these two compounds.
Moreover, unlike the earlier described and apparently
metabolicallyunstableTZTPderivatives[25],the3β-phenyl-
6β-acetoxynortropane (10a)a n d3 α-hydroxy-3β-phenyl-6β-6 International Journal of Molecular Imaging
acetoxynortropane (10b) should be more metabolically
stable due to the direct substitution of the phenyl ring to the
tropane skeleton, which is known to have favorable eﬀects
on the in vivo stability of tropane-derived radiotracers such
as [123I]FP-CIT [31, 32]o r[ 123I]β-CIT [33].
In our competitive binding experiments, the inhibition
constant of the original compound 6β-acetoxynortropane
(5a) was substantially higher than the Ki that was described
by Pei and coworkers [27]. Reasons for this may include
diﬀerences in the reference tracer, which was [3H]NMS
in the present experiments, whereas Pei et al. used
[3H]quinuclidinyl benzilate (QNB), as well as a diﬀerence
between rat and human muscarinic receptors. Pei et al.
demonstrated a Ki of 2.6nM for 6β-acetoxynortropane at
the muscarinic M2 receptor and very high selectivity ratios
overeither M1 or M3 receptors using the tritiated antagonist.
In the same study, an even lower inhibition constant was
reported by Pei et al. when using the muscarinic agonist
[3H]oxotremorine as a reference. In our study, using only
[3H]NMS but not [3H]oxotremorine as a reference, we
calculated Ki values to the M2 receptor of 71 and 88nM,
in two separate series of competitive binding experiments
using diﬀerent protocols, and lower selectivity ratios to M1
and M3 receptors of 65 and 70, respectively. Nevertheless,
such selectivity ratios would be very adequate for imaging of
muscarinicM2 receptorsinvivo.However,theiodinatedana-
loguesthat were tested(5band 5c) onlyshowed weak aﬃnity
forall three tested muscarinic receptorsubtypes, whereas the
Ki of either 3β-phenyl-6β-acetoxynortropane (10a) or 3α-
hydroxy-3β-phenyl-6β-acetoxynortropane (10b) could not
be assessed, but proved to be above the micromolar range.
We tested the derivatives at a maximal concentration of
10−5 M, which may be a limitation of the present study,
but Ki values in the micromolar range or higher were
not considered of interest for our purposes. However, it
c a n n o tb ee x c l u d e dt h a ti o d i n a t i o no fd e r i v a t i v e10aand 10b
would result in improved aﬃnities for muscarinic receptors.
Also, substitution of the phenyl group at the 3α-positition,
which is known to have bulk tolerance in tropane-derived
radiotracers (and muscarinic receptor antagonists such as
atropine, NMS, and benztropine), may improve the in vitro
binding characteristics.
In conclusion, we synthesized a series of analogues to
6β-acetoxynortropane, potentially being of interest for use
as radiotracers for in vivo imaging of the muscarinic M2
receptor subtype in neurodegenerative or neuropsychiatric
diseases. However, changing the original molecule on the
6β-o rt h e3 α/β-position by substitution of a iodophenyl or
phenyl ring severely reduced both the aﬃnity and selectivity
of the nortropane for the muscarinic M2 receptor subtype,
and therefore, the synthesized analogues are not suitable for
use in human SPECT imaging.
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